Table 3 Treatment-emergent adverse events†
Event | Weeks 1–8, n (%) | Weeks 9–52, n (%) | Weeks 1–52, n (%) |
|---|---|---|---|
Nausea | 29 (28.7) | 0 (0.0) | 29 (28.7) |
Dizziness | 27 (26.7) | 5 (5.0) | 31 (30.7) |
Somnolence | 22 (21.8) | 1 (1.0) | 23 (22.8) |
Constipation | 20 (19.8) | 5 (5.0) | 23 (22.8) |
Dry mouth | 16 (15.8) | 4 (4.0) | 18 (17.8) |
Insomnia | 15 (14.9) | 8 (7.9) | 22 (21.8) |
Headache | 11 (10.9) | 6 (5.9) | 16 (15.8) |
Increased sweating | 11 (10.9) | 4 (4.0) | 15 (14.9) |
Diarrhea | 11 (10.9) | 6 (5.9) | 17 (16.8) |
Tremor | 7 (6.9) | 2 (2.0) | 9 (8.9) |
Anxiety NEC | 7 (6.9) | 3 (3.0) | 10 (9.9) |
Fatigue | 7 (6.9) | 4 (4.0) | 9 (8.9) |
Decreased appetite | 7 (6.9) | 1 (1.0) | 7 (6.9) |
Vomiting | 7 (6.9) | 3 (3.0) | 10 (9.9) |
Anorexia | 6 (5.9) | 3 (3.0) | 8 (7.9) |
Back pain | 5 (5.0) | 2 (2.0) | 6 (5.9) |
Abdominal pain upper | 4 (4.0) | 2 (2.0) | 6 (5.9) |